Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 0.80 |
| ▸ | RAB9A | P51151 | 7/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | C1R | P00736 | 7/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8898698 | 0.89 | ELANE (0.80) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3453350 | 0.89 | ELANE (0.80) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3452177 | 0.89 | ELANE (0.80) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3452148 | 0.89 | ELANE (0.80) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3452339 | 0.89 | ELANE (0.80) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3453188 | 0.87 | ELANE (0.76) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3453070 | 0.87 | ELANE (0.76) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3452779 | 0.85 | ELANE (0.74) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL8896637 | 0.85 | ELANE (0.74) | ELANENPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3452527 | 0.85 | ELANE (0.74) | ELANENPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | claimed |
| EP-1144395-B1 | 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2005-04-20 | — | — | EP | claimed |
| US-6656934-B2 | Enzyme inhibitor | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-12-02 | — | — | US | claimed |
| US-20030191123-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2003-10-09 | — | — | US | claimed |
| US-20030013707-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2003-01-16 | — | — | US | claimed |
| WO-2000040569-A9 | 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2002-02-28 | — | — | WO | claimed |
| EP-1143977-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | Alizyme Therapeutics Limited (GB) | 2001-10-17 | — | — | EP | claimed |
| WO-2000040247-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LIMITED (GB) | 2000-07-13 | — | — | WO | claimed |
| WO-1996007648-A1 | 2-SUBSTITUTED-4H-3,1-BENZOXAZIN-4-ONES AND BENZTHIAZIN-4-ONES AS INHIBITORS OF COMPLEMENT Clr PROTEASE FOR THE TREATMENT OF INFLAMMATORY PROCESSES | WARNER-LAMBERT COMPANY (US) | 1996-03-14 | — | — | WO | claimed |
| WO-2025099141-A1 | STABILIZING COMPOSITIONS FOR POLYMERIC MATERIALS | CYTEC INDUSTRIES INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025099143-A1 | COMPOSITIONS FOR STABILIZING POLYMERIC MATERIALS AGAINST UV LIGHT THERMAL AND GAS FADING DEGRADATION | CYTEC INDUSTRIES INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | disclosed |
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | disclosed |
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | disclosed |
| WO-2001003697-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | G.D. SEARLE & CO. (US) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000040247-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LIMITED (GB) | 2000-07-13 | — | — | WO | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5652237-A | 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes | WARNER-LAMBERT COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996007648-A1 | 2-SUBSTITUTED-4H-3,1-BENZOXAZIN-4-ONES AND BENZTHIAZIN-4-ONES AS INHIBITORS OF COMPLEMENT Clr PROTEASE FOR THE TREATMENT OF INFLAMMATORY PROCESSES | WARNER-LAMBERT COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191123-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | CYP4X1, CYP2B6, BBOX1 | ELANE 730/4885NPC1 2324/4885RAB9A 3075/4885 |
| US-20030013707-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | CYP4X1, CYP2B6, BBOX1 | ELANE 730/4885NPC1 2324/4885RAB9A 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.